“And also, whether data comes in the affirmative or negative, IMHO Cytodyn’s data will be high quality, fully distilled data.”

Let’s hope so because the M2M PRs were a mess (one had to be released a second time) and the M2M full data has yet to be published. CYDY should let Dr. Mahoob write the PR like a solid Mesoblast PR. We cannot flub the S/C trial PR: make the title short and sweet and to the point.